06.01.06
Research Highlights
CORvalen Improves Pain and Quality of Life in
Fibromyalgia and Chronic Fatigue Patients
The results of an open label, 41-patient feasibility study on CORvalen D-ribose, from Bioenergy, Inc., Minneapolis, MN, and its effects on fibromyalgia and/or chronic fatigue were recently released. Jacob Teitelbaum, MD, medical director of the Center for Effective CFS/Fibromyalgia Therapies, Annapolis, MD, along with Valen Labs conducted the study, which had two endpoints: assessing the level of relief in symptoms of fatigue and pain; and determining changes in patient quality of life. The patients in the study had an average age of 48 years and 78% of the patient population was female, which is in keeping with the prevalence in the general population, as fibromyalgia and chronic fatigue syndrome affect twice as many women as men and typically first appears at middle age. At the start of the study the patients completed a 10-point quality of life (QOL) visual analog scale and then took five grams of CORvalen D-ribose orally three times a day for an average of 28 days. After the 28-day treatment period the QOL questionnaire was repeated, and 69% of the 36 patients who completed the course of CORvalen treatment had significant improvement in their symptoms. They also averaged a 25% improvement in the QOL scale. The study proved the energy building benefit of ribose directly improved the debilitating symptoms of fibromyalgia and chronic fatigue syndrome.
UroLogic Effectively Reduces Symptoms of Overactive
Bladder and Urinary Incontinence
BioLogic Health Solutions Pty Ltd., Brisbane, Australia, has released the results of a two-month clinical trial confirming that its proprietary, all-natural ingredient UroLogic helps reduce symptoms of overactive bladder and urinary incontinence in men and women. The two-month randomized, double-blind, placebo controlled trial of 73 men and women, ages 29-88, revealed that 85% of participants receiving UroLogic demonstrated significant reduction in symptoms, including frequency of urination and/or incidence of leakage after two months. Of the participants in the UroLogic group, 70% noted an increase in their quality
CORvalen Improves Pain and Quality of Life in
Fibromyalgia and Chronic Fatigue Patients
The results of an open label, 41-patient feasibility study on CORvalen D-ribose, from Bioenergy, Inc., Minneapolis, MN, and its effects on fibromyalgia and/or chronic fatigue were recently released. Jacob Teitelbaum, MD, medical director of the Center for Effective CFS/Fibromyalgia Therapies, Annapolis, MD, along with Valen Labs conducted the study, which had two endpoints: assessing the level of relief in symptoms of fatigue and pain; and determining changes in patient quality of life. The patients in the study had an average age of 48 years and 78% of the patient population was female, which is in keeping with the prevalence in the general population, as fibromyalgia and chronic fatigue syndrome affect twice as many women as men and typically first appears at middle age. At the start of the study the patients completed a 10-point quality of life (QOL) visual analog scale and then took five grams of CORvalen D-ribose orally three times a day for an average of 28 days. After the 28-day treatment period the QOL questionnaire was repeated, and 69% of the 36 patients who completed the course of CORvalen treatment had significant improvement in their symptoms. They also averaged a 25% improvement in the QOL scale. The study proved the energy building benefit of ribose directly improved the debilitating symptoms of fibromyalgia and chronic fatigue syndrome.
UroLogic Effectively Reduces Symptoms of Overactive
Bladder and Urinary Incontinence
BioLogic Health Solutions Pty Ltd., Brisbane, Australia, has released the results of a two-month clinical trial confirming that its proprietary, all-natural ingredient UroLogic helps reduce symptoms of overactive bladder and urinary incontinence in men and women. The two-month randomized, double-blind, placebo controlled trial of 73 men and women, ages 29-88, revealed that 85% of participants receiving UroLogic demonstrated significant reduction in symptoms, including frequency of urination and/or incidence of leakage after two months. Of the participants in the UroLogic group, 70% noted an increase in their quality
